OmniSeq Staff, Author at OmniSeq

Clinical and Translational Director of Next Generation Sequencing

by OmniSeq Staff | Sep 1, 2017 | Uncategorized

Position Description: OmniSeq is seeking a MD/DO-licensed Molecular Pathologist, licensed to practice medicine in New York State or with the ability to obtain a NYS license. The applicant will direct a CLIA CAP and NYS state-of- the-art next generation sequencing...

Follow Us on Twitter

OmniSeq Follow

Finding the right drug or the right trial...for every #cancer patient. #immunotherapy Pronounced OmniSeek

Avatar OmniSeq @omniseq ·

4 Nov

This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today: https://bit.ly/3NAKg3S

Reply on Twitter 1588584498606014465 Retweet on Twitter 1588584498606014465 Like on Twitter 1588584498606014465 Twitter 1588584498606014465

Avatar OmniSeq @omniseq ·

3 Jun

LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine

Reply on Twitter 1532751537994342401 Retweet on Twitter 1532751537994342401 Like on Twitter 1532751537994342401 5 Twitter 1532751537994342401

Avatar OmniSeq @omniseq ·

27 May

June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
#2561-Developmental Therapeutics—Immunotherapy
Sunday, June 5, 8-11:00 AM CDT

Reply on Twitter 1530217104867196928 Retweet on Twitter 1530217104867196928 Like on Twitter 1530217104867196928 3 Twitter 1530217104867196928

Avatar OmniSeq @omniseq ·

27 May

June 3-7 | Chicago, IL Join us at the @ASCO 2022. Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance.
#376244-Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

Reply on Twitter 1530216482998734850 Retweet on Twitter 1530216482998734850 Like on Twitter 1530216482998734850 3 Twitter 1530216482998734850

Avatar OmniSeq @omniseq ·

27 May

June 3-7 | Chicago, IL Join us at the 2022 ASCO Annual Meeting.
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC.
#2623 -Developmental Therapeutics—Immunotherapy
Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

Reply on Twitter 1530215721862680578 Retweet on Twitter 1530215721862680578 Like on Twitter 1530215721862680578 1 Twitter 1530215721862680578